Glaukos posts investor presentation outlining iDose TR, Epioxa launch and pipeline depth
Glaukos (GKOS) filed and posted an investor presentation outlining progress for iDose TR, including FDA re-administration approval in Jan 2026 for up to 3 years of therapy, and the March 2026 launch of Epioxa for keratoconus. It also cites a pipeline of 13 programs and 2026 revenue guidance midpoint of about $690M, with $289M cash and no debt as of 6/30/2026.
How this was made
The 30-second read
Why it matters
For traders, the most decision-relevant elements are the time-specific product milestones (iDose TR re-administration approval in Jan 2026, Epioxa availability in March 2026) and the quantified 2026 revenue guidance midpoint (~$690M) with cash and margin metrics.
Market read
This is a company-specific, forward-looking commercial and financial update that can affect expectations for 2026 ophthalmology revenue and product adoption.
What to watch
Key risks are execution and payer uptake for Epioxa and sustained demand for iDose TR; the article does not quantify launch uptake, reimbursement outcomes, or competitive dynamics.
Background
The company filed an Exhibit 99.1 investor presentation under Regulation FD and summarized commercial progress for iDose TR and the upcoming Epioxa launch, alongside pipeline breadth and financial posture.
Ticker impact
Glaukos filed and posted an investor presentation detailing iDose TR re-administration approval, Epioxa launch timing, and 2026 revenue guidance.
Moderate upside bias if investors view the Epioxa launch and iDose TR durability as de-risking 2026 revenue toward the ~$690M midpoint.
The article provides specific, time-stamped commercial milestones (Epioxa available March 2026, iDose TR re-administration approved Jan 2026) plus quantified guidance and cash/debt posture, which are actionable for positioning.
Market effects
Could improve sentiment toward ophthalmology specialty pharma commercialization execution, especially long-duration glaucoma implants and keratoconus topical therapies.
Primarily US-focused investor narrative via SEC Reg FD filing; limited direct regional spillover implied.
May influence global expectations for ophthalmic product durability and payer adoption, but no ex-US regulatory or launch details are provided.
Counterpoint
Investor presentations can be marketing-forward; without new clinical efficacy data or updated trial readouts, the market may already be pricing the trajectory.
Key entities
- public_companyGlaukos
Subject of the Reg FD investor presentation covering iDose TR, Epioxa, pipeline programs, and 2026 guidance.
- productiDose TR
FDA-approved long-duration travoprost implant with re-administration approved Jan 2026, targeting up to 3 years of therapy.
- productEpioxa
Epi-on keratoconus topical therapy described as commercially available March 2026 with launch infrastructure and payer efforts underway.
